At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 321 enrolled
Drug / intervention
DS107 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Placebo-controlled, Phase 2b Study to Assess the Efficacy and Safety of Orally Administered DS107 in Patients With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating DS107 and Placebo for Atopic Dermatitis. Completed, enrolled 321 participants across 2 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine whether orally administered DS107 (1g and 2g doses) is effective in the treatment of moderate to severe atopic dermatitis. Oral DS107 capsules will be administered for 8 weeks and will be compared against placebo. The study will enroll approximately 300 subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesSouth Africa, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartJan 2017
Primary CompletionJun 2018
TodayJul 2026
First PostedAug 12, 2016
Enrollment StartJan 1, 2017
Primary CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.9 years ago
Interventions
DS107drug
Placebodrug